Tempest Therapeutics Inc (TPST) — Cash Flow-to-Debt Ratio
Tempest Therapeutics Inc (TPST) has a Cash Flow-to-Debt Ratio of -0.77x as of March 2026, meaning its operating cash flow of $-7.60 Million could theoretically repay -1% of its total liabilities ($9.93 Million) in one year. Check cash flow reinvestment rate of Tempest Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tempest Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Tempest Therapeutics Inc across 14 annual periods. Also explore Tempest Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tempest Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Tempest Therapeutics Inc. For market capitalisation and broader financial context, see TPST market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-26.82 Million | $10.26 Million | ▼ -76.9% |
| 2024 | -1.48x | $-33.03 Million | $22.36 Million | ▼ -34.1% |
| 2023 | -1.10x | $-27.36 Million | $24.84 Million | ▲ +0.8% |
| 2022 | -1.11x | $-31.07 Million | $27.98 Million | ▼ -58.8% |
| 2021 | -0.70x | $-25.96 Million | $37.12 Million | ▼ -237.0% |
| 2020 | -0.21x | $-19.02 Million | $91.66 Million | ▲ +92.4% |
| 2019 | -2.73x | $-41.22 Million | $15.10 Million | ▼ -26.4% |
| 2018 | -2.16x | $-23.65 Million | $10.95 Million | ▲ +48.7% |
| 2017 | -4.21x | $-20.34 Million | $4.83 Million | ▲ +2.3% |
| 2016 | -4.31x | $-61.73 Million | $14.32 Million | ▼ -0.8% |
| 2015 | -4.27x | $-50.29 Million | $11.76 Million | ▼ -43.2% |
| 2014 | -2.99x | $-30.59 Million | $10.25 Million | ▲ +3.6% |
| 2013 | -3.10x | $-18.09 Million | $5.84 Million | ▲ +41.9% |
| 2012 | -5.33x | $-11.16 Million | $2.09 Million | — |